Houghton PJ - Search Results

1

Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.

Children's Oncology Group; Fouladi M, Furman WL, Chin T, Freeman BB 3rd, Dudkin L, Stewart CF, Krailo MD, Speights R, Ingle AM, Houghton PJ, Wright J, Adamson PC, Blaney SM. Children's Oncology Group, et al. Among authors: houghton pj. J Clin Oncol. 2006 Aug 1;24(22):3678-85. doi: 10.1200/JCO.2006.06.4964. J Clin Oncol. 2006. PMID: 16877737 Clinical Trial.

2

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.

Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Houghton PJ, et al. Among authors: houghton ja. Cancer Chemother Pharmacol. 1992;31(3):229-39. doi: 10.1007/BF00685553. Cancer Chemother Pharmacol. 1992. PMID: 1464161

3

Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development.

Horowitz ME, Etcubanas E, Christensen ML, Houghton JA, George SL, Green AA, Houghton PJ. Horowitz ME, et al. Among authors: houghton ja, houghton pj. J Clin Oncol. 1988 Feb;6(2):308-14. doi: 10.1200/JCO.1988.6.2.308. J Clin Oncol. 1988. PMID: 3276826 Clinical Trial.

4

P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma.

Kuttesch JF, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT, Houghton PJ. Kuttesch JF, et al. Among authors: houghton pj. J Clin Oncol. 1996 Mar;14(3):886-900. doi: 10.1200/JCO.1996.14.3.886. J Clin Oncol. 1996. PMID: 8622037

5

Topoisomerase I interactive drugs in children with cancer.

Stewart CF, Zamboni WC, Crom WR, Gajjar A, Heideman RL, Furman WL, Meyer WH, Houghton PJ, Pratt CB. Stewart CF, et al. Among authors: houghton pj. Invest New Drugs. 1996;14(1):37-47. doi: 10.1007/BF00173681. Invest New Drugs. 1996. PMID: 8880392 Review.

6

Schedule-dependent efficacy of camptothecins in models of human cancer.

Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Luo X, Danks MK, Houghton JA. Houghton PJ, et al. Among authors: houghton ja. Ann N Y Acad Sci. 1996 Dec 13;803:188-201. doi: 10.1111/j.1749-6632.1996.tb26388.x. Ann N Y Acad Sci. 1996. PMID: 8993512 No abstract available.

7

Efficacy of oral irinotecan against neuroblastoma xenografts.

Thompson J, Zamboni WC, Cheshire PJ, Richmond L, Luo X, Houghton JA, Stewart CF, Houghton PJ. Thompson J, et al. Among authors: houghton ja, houghton pj. Anticancer Drugs. 1997 Apr;8(4):313-22. doi: 10.1097/00001813-199704000-00002. Anticancer Drugs. 1997. PMID: 9180383

8

Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.

Stewart CF, Zamboni WC, Crom WR, Houghton PJ. Stewart CF, et al. Among authors: houghton pj. Cancer Chemother Pharmacol. 1997;40(3):259-65. doi: 10.1007/s002800050656. Cancer Chemother Pharmacol. 1997. PMID: 9219511

9

Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.

Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo X, Stewart CF. Zamboni WC, et al. Among authors: houghton pj. J Pharmacol Exp Ther. 1998 Jan;284(1):89-94. J Pharmacol Exp Ther. 1998. PMID: 9435165

10

Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.

Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X, Stewart CF. Zamboni WC, et al. Among authors: houghton pj. Clin Cancer Res. 1998 Feb;4(2):455-62. Clin Cancer Res. 1998. PMID: 9516936

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

591 results

Search Page

Filters